Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Safety of Different Specifications of SHR-3167 Injection in Healthy Subjects
NCT07489482Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SHR-3167 in diabetes mellitus (DM) (3 arms), sponsored by Hengrui. Primary endpoints: Maximum plasma concentration, Area under the blood drug concentration-time curve from time 0 to the last quantifiable concentration time and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
SHR-3167
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT07489482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489482.